Mark C. McKenna - Nov 14, 2021 Form 4 Insider Report for Prometheus Biosciences, Inc. (RXDX)

Role
Chairman, President & CEO, Director
Signature
/s/ Timothy K. Andrews, attorney-in-fact for Mark C. McKenna
Stock symbol
RXDX
Transactions as of
Nov 14, 2021
Transactions value $
$0
Form type
4
Date filed
11/16/2021, 08:03 PM
Next filing
Dec 3, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXDX Stock Option (Right to Buy) Award $0 +290K $0.00 290K Nov 14, 2021 Common Stock 290K $36.32 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option will vest on November 14, 2022, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer through each vest date.